FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284989100> ?p ?o ?g. }

• W4284989100 endingPage "491.e9" @default.
• W4284989100 startingPage "491.e1" @default.
• W4284989100 abstract "To re-evaluate the treatment of T1HG bladder cancer by analyzing our experience over 18 years.An IRB-approved, single-institution retrospective review was performed of all patients with T1HG bladder cancer between August 1999 and July 2017. We assessed clinicopathologic characteristics, treatment history (including intravesical therapy, cystectomy, systemic chemotherapy, and radiation), and oncologic outcomes.We identified 191 patients with T1HG. Five patients underwent cystectomy at diagnosis. The five-year recurrence-free survival (RFS) for the 186 patients who initially underwent bladder sparing treatments was 50% (95% CI: 41%-58%). There were 83 patients (45%) with disease recurrence; median time to recurrence was 6.7 months (IQR: 4.9-17.5). Disease characteristics at initial recurrence was T2 or greater in 8 patients (10%), T1HG in 19 (23%), CIS in 30 (36%), TaHG in 10 (12%), T1 low-grade (LG) in 1 (1%), and TaLG in 15 (18%). For patients with no prior recurrences, neither re-resection (P = 0.12), receipt of induction therapy (P = 0.81), prostatic urethra positivity (P = 0.51), or age (P = 0.34) were significantly associated with risk of recurrence. Similarly, patients with a single recurrence also fared well without identifiable risk factors. In fact, baseline hazard function analysis demonstrated no differences in RFS comparing patients stratified by 0, 1, and 2+ prior recurrences (P = 0.46). The five-year overall survival (OS) was 76% (95% CI: 68%-82%), and median OS was 127 months. The five-year cancer-specific survival was 86% (95% CI: 78%-91%) for the overall cohort. Five-year cystectomy-free survival for patients with BCG responsive disease and unresponsive disease was 95% (95% CI: 85%-98%) and 72% (95% CI: 52%-84%), respectively.For patients who recurred after intravesical therapy, including those with recurrent T1 disease, additional induction courses of intravesical therapy did not negatively affect oncologic outcomes. Pathology of initial recurrence was not found to be a statistically significant risk factor for future recurrence. These findings suggest that BCG-unresponsive disease does not necessarily require immediate cystectomy. A multicenter, pragmatically designed evaluation in a contemporary cohort would more validly interrogate this important patient population." @default.
• W4284989100 created "2022-07-11" @default.
• W4284989100 creator A5000200605 @default.
• W4284989100 creator A5003263712 @default.
• W4284989100 creator A5024635449 @default.
• W4284989100 creator A5038856704 @default.
• W4284989100 creator A5083626538 @default.
• W4284989100 date "2022-11-01" @default.
• W4284989100 modified "2023-10-11" @default.
• W4284989100 title "A longitudinal single center analysis of T1HG bladder cancer: An 18 year experience" @default.
• W4284989100 cites W130638139 @default.
• W4284989100 cites W1571103639 @default.
• W4284989100 cites W1984718148 @default.
• W4284989100 cites W2013938985 @default.
• W4284989100 cites W2017802509 @default.
• W4284989100 cites W2031736835 @default.
• W4284989100 cites W2065151446 @default.
• W4284989100 cites W2082926032 @default.
• W4284989100 cites W2104759746 @default.
• W4284989100 cites W2112452983 @default.
• W4284989100 cites W2113156769 @default.
• W4284989100 cites W2122267678 @default.
• W4284989100 cites W2139481981 @default.
• W4284989100 cites W2149343996 @default.
• W4284989100 cites W2155212834 @default.
• W4284989100 cites W2156164249 @default.
• W4284989100 cites W2270022169 @default.
• W4284989100 cites W2345115264 @default.
• W4284989100 cites W2443056117 @default.
• W4284989100 cites W2772863724 @default.
• W4284989100 cites W2795278882 @default.
• W4284989100 cites W2884458916 @default.
• W4284989100 cites W2889250776 @default.
• W4284989100 cites W2894680519 @default.
• W4284989100 cites W2948036697 @default.
• W4284989100 cites W2969983122 @default.
• W4284989100 cites W3010996954 @default.
• W4284989100 cites W3020369374 @default.
• W4284989100 cites W3041422400 @default.
• W4284989100 cites W3092815757 @default.
• W4284989100 cites W3122056362 @default.
• W4284989100 cites W3196804058 @default.
• W4284989100 cites W4242669880 @default.
• W4284989100 cites W4251083747 @default.
• W4284989100 cites W594984707 @default.
• W4284989100 doi "https://doi.org/10.1016/j.urolonc.2022.06.007" @default.
• W4284989100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35831215" @default.
• W4284989100 hasPublicationYear "2022" @default.
• W4284989100 type Work @default.
• W4284989100 citedByCount "2" @default.
• W4284989100 countsByYear W42849891002022 @default.
• W4284989100 countsByYear W42849891002023 @default.
• W4284989100 crossrefType "journal-article" @default.
• W4284989100 hasAuthorship W4284989100A5000200605 @default.
• W4284989100 hasAuthorship W4284989100A5003263712 @default.
• W4284989100 hasAuthorship W4284989100A5024635449 @default.
• W4284989100 hasAuthorship W4284989100A5038856704 @default.
• W4284989100 hasAuthorship W4284989100A5083626538 @default.
• W4284989100 hasConcept C121608353 @default.
• W4284989100 hasConcept C126322002 @default.
• W4284989100 hasConcept C126894567 @default.
• W4284989100 hasConcept C141071460 @default.
• W4284989100 hasConcept C167135981 @default.
• W4284989100 hasConcept C207103383 @default.
• W4284989100 hasConcept C2775910329 @default.
• W4284989100 hasConcept C2780073493 @default.
• W4284989100 hasConcept C2780352672 @default.
• W4284989100 hasConcept C38180746 @default.
• W4284989100 hasConcept C44249647 @default.
• W4284989100 hasConcept C50382708 @default.
• W4284989100 hasConcept C509974204 @default.
• W4284989100 hasConcept C71924100 @default.
• W4284989100 hasConcept C72563966 @default.
• W4284989100 hasConceptScore W4284989100C121608353 @default.
• W4284989100 hasConceptScore W4284989100C126322002 @default.
• W4284989100 hasConceptScore W4284989100C126894567 @default.
• W4284989100 hasConceptScore W4284989100C141071460 @default.
• W4284989100 hasConceptScore W4284989100C167135981 @default.
• W4284989100 hasConceptScore W4284989100C207103383 @default.
• W4284989100 hasConceptScore W4284989100C2775910329 @default.
• W4284989100 hasConceptScore W4284989100C2780073493 @default.
• W4284989100 hasConceptScore W4284989100C2780352672 @default.
• W4284989100 hasConceptScore W4284989100C38180746 @default.
• W4284989100 hasConceptScore W4284989100C44249647 @default.
• W4284989100 hasConceptScore W4284989100C50382708 @default.
• W4284989100 hasConceptScore W4284989100C509974204 @default.
• W4284989100 hasConceptScore W4284989100C71924100 @default.
• W4284989100 hasConceptScore W4284989100C72563966 @default.
• W4284989100 hasIssue "11" @default.
• W4284989100 hasLocation W42849891001 @default.
• W4284989100 hasLocation W42849891002 @default.
• W4284989100 hasOpenAccess W4284989100 @default.
• W4284989100 hasPrimaryLocation W42849891001 @default.
• W4284989100 hasRelatedWork W2109785281 @default.
• W4284989100 hasRelatedWork W2189722039 @default.
• W4284989100 hasRelatedWork W2383341741 @default.
• W4284989100 hasRelatedWork W2595618663 @default.
• W4284989100 hasRelatedWork W2899655305 @default.

• next